A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Trial Details

NCT ID

NCT07102381

Phase

PHASE2

Sponsor

Jazz Pharmaceuticals

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

Zanidatamab
Paclitaxel
Docetaxel
Carboplatin
Trastuzumab
Pertuzumab

Locations (sample)

Long Beach, California, United States|33.76696,-118.18923
Denver, Colorado, United States|39.73915,-104.9847
Lakeland, Florida, United States|28.03947,-81.9498
Ames, Iowa, United States|42.03471,-93.61994
Shreveport, Louisiana, United States|32.52515,-93.75018

Key Eligibility Criteria

Has Stage II or III histologically confirmed invasive breast carcinoma.
Has histologically confirmed HER2-positive breast cancer
Has a known hormone receptor (HR) status of the primary tumor
Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →